ZKB BARRIER REVERSE CONVERTIBLE ON WORST OF - ABBVIE/MERCK & CO./ELI LILLY & CO ZKB BARRIER REVERSE CONVERTIBLE ON WORST OF - ABBVIE/MERCK & CO./ELI LILLY & CO Stock
Certificat
Z07YCZ
CH1273443221
| Market Closed - Swiss Exchange 11:20:00 2024-05-17 EDT | ||
| 103.7 USD | +0.02% |
|
| Current month | +0.29% | ||
| 1 month | +0.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 103.7 | +0.02% |
| 24-05-16 | 103.6 | +0.04% |
| 24-05-15 | 103.6 | +0.02% |
| 24-05-14 | 103.6 | +0.01% |
| 24-05-13 | 103.6 | +0.02% |
Delayed Quote Swiss Exchange
Last update May 17, 2024 at 11:20 am
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | ZKB |
| Z07YCZ | |
| ISIN | CH1273443221 |
| Date issued | 2023-07-24 |
| Strike | 459.3 $ |
| Maturity | 2024-07-24 (67 Days) |
| Parity | 0.46 : 1 |
| Emission price | 100 $ |
| Emission volume | N/A |
| Settlement | both |
| Currency | USD |
Technical Indicators
| Highest since issue | 107.1 $ |
|---|---|
| Lowest since issue | 100.5 $ |
| Spread | 6 $ |
| Spread % | 0.58% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- Z07YCZ Certificat
